Edison (New Jersey): India has emerged as one of the leading vaccine manufacturer in recent times, producing 60 per cent of the global health vaccines.
Exports have a major share in the Indian vaccine market, with 70 per cent vaccines being exported. Of the total domestic market, the private sector`s share stood at USD 120 million or at 40 per cent. Top vaccine manufacturers have a reasonably diverse product portfolio which has led to reduced competition in the Indian market. The Indian market includes foreign majors like GSK, Sanofi, Eli Lily, and Merck to name some. But the scene is essentially dominated by Indian players such as Green Signal Bio Pharma based in Chennai who have gained significant expertise in manufacturing practices for macromolecules with quality but at low cost and have capitalized on the rising global demand for affordable vaccines, he said. The global vaccine market grew at a healthy 28 per cent during 2005-08 and reached a size of approximately USD 20 billion. Growth from the sales of vaccines has surpassed the growth in many traditional pharma areas of vaccine manufacturers such as GSK, Merck, Wyeth and Sanofi Aventis.Globally, the US recorded the largest share in the vaccine market at around 43 per cent and Europe is the second largest vaccine market and source of production. However, it is estimated that in the future more opportunities for manufacture and sales of vaccines will emerge from developing nations such as India and China, he said. Prof. Myint, an eminent senior board level physician with experience in public health, academia and biopharmaceutical industries is a well ? known strategist, planner and organizational leader supported by outstanding research and analytical skills. He took over as chairman of Green Signal Pharma Private Limited from its founder-presidentN Sundar Paripoornan in Jan 2011. PTI
Elections 2014: Bollywood stars turn out to vote
Will Modi`s lucky pen make him the PM?
Election Superfast @8:30am
SC forms 3 member committee for govt advertisements